Subscribe
Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine for potential distribution in low- and middle-income countries.
Novartis Strikes Deal to Acquire Anthos Therapeutics
Abcuro Secures $200 Million in Series C Funding to Advance Ulviprubart for Inclusion Body Myositis
ImmunityBio, BeiGene Strike Deal to Conduct Phase III Trial for Tislelizumab, Anktiva in Advanced or Metastatic Non-Small Cell Lung Cancer
